Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR5088914

—

0a84cd92-6c1f-5345-b6c1-11a3fa7c47ae

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
  • ANGIOGENESIS+0.500
  • TGF_BETA_SIGNALING+0.500
  • WNT_BETA_CATENIN_SIGNALING+0.500
  • APICAL_JUNCTION+0.400
  • NOTCH_SIGNALING+0.400
  • UV_RESPONSE_DN+0.400
  • CHOLESTEROL_HOMEOSTASIS+0.300
  • COAGULATION+0.300
  • INTERFERON_ALPHA_RESPONSE+0.300

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.400
  • SPERMATOGENESIS-0.300
  • ADIPOGENESIS-0.200
  • FATTY_ACID_METABOLISM-0.200
  • KRAS_SIGNALING_DN-0.200
  • MYC_TARGETS_V1-0.200
  • MYC_TARGETS_V2-0.200
  • XENOBIOTIC_METABOLISM-0.200
  • BILE_ACID_METABOLISM-0.100
  • GLYCOLYSIS-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-FD-A62S-01A-11R-A30C-07
bladder-landscape@3
——0.840
2TCGA-85-8582-01A-21R-2403-07
lung-landscapes@6
—cohortSQ10.838
3TCGA-56-6545-01A-11R-1820-07
lung-landscapes@6
—cohortSQ10.803
4TCGA-86-8075-01A-11R-2241-07
lung-landscapes@6
—cohortA10.772
5TCGA-85-8353-01A-21R-2296-07
lung-landscapes@6
—cohortSQ10.765
6TCGA-FD-A3SP-01A-31R-A22U-07
bladder-landscape@3
——0.765
7SAMN03290942
melanoma-umap@29
——0.761
8TCGA-44-7662-01A-11R-2066-07
lung-landscapes@6
—cohortA10.760
9b9cadac9-9bb4-4bc8-9303-d05ad06778cc
colon-landscapes@1
——0.757
10SAMN03290934
melanoma-umap@29
——0.757

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.600Inavolisib— uncovered
ANGIOGENESIS0.500Remibrutinib— uncovered
TGF_BETA_SIGNALING0.500Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.500Inavolisib— uncovered
APICAL_JUNCTION0.400Inavolisib— uncovered
NOTCH_SIGNALING0.400Inavolisib— uncovered
UV_RESPONSE_DN0.400Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
COAGULATION0.300Binimetinib— uncovered
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.300Inavolisib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.300Idelalisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
E2F_TARGETS0.200Inavolisib— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.200Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered